References
- Friedl P, Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev 2009;28:129–35
- Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007;9:893–904
- Galvez BG, Matias-Roman S, Albar JP, et al. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001;276:37491–500
- Wang X, Ma D, Keski-Oja J, Pei D. Co-recycling of MT1-MMP and MT3-MMP through the Trans-Golgi Network. J Biol Chem 2004;279:9331–6
- Monteiro P, Rossé C, Castro-Castro A, et al. Endosomal WASH and exocyst complexes control exocytosis of MT1-MMP at invadopodia. J Cell Biol 2013;203:1063–79
- Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4
- Ottl J, Gabriel D, Murphy G, et al. Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. Chem Biol 2000;7:119–32
- Suojanen J, Salo T, Koivunen E, et al. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther 2009;8:2362–70
- Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517–26
- Kaimal R, Aljumaily R, Tressel SL, et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 2013;73:2457–67
- Zhu L, Wang H, Wang L, et al. High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release 2011;150:248–55
- Zarrabi K, Dufour A, Li J, et al. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 2011;286:33167–77
- Jani M, Tordai H, Trexler M, et al. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2. Biochimie 2005;87:385–92
- Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005;280:33992–4002
- Hurst DR, Schwartz MA, Jin Y, et al. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. Biochem J 2005;392:527–36
- Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012;72:2339–49
- Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1–8
- Kortylewicz Z, Galardy RE. Phosphoramidate peptide inhibitors of human skin fibroblast collagenase. J Med Chem 1990;33:263–73
- Rao BG. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005;11:295–322
- Grossman M, Tworowski D, Dym O, et al. The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry 2010;49:6184–92
- Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998;17:5238–48